2 - BACTERIOWEB
2 - BACTERIOWEB 2 - BACTERIOWEB
Efflux mechanisms: practical implications Do efflux systems produce clinically relevant levels of resistance ? Does the expression of drug transporters impair the virulence of bacterial pathogens ? What is the prevalence of efflux systems relative to other resistance mechanisms among the clinical isolates ? How to recognize efflux mutants in laboratory practice ? What recommendations can be made to the physician for the treatment of patients infected with mdr strains ? 10
Structure of bacterial efflux systems One component systems – Mostly in Gram positive species (except Tet...) – A single transporter protein in the cytoplasmic membrane – Determines the substrate specificity and resistance Three component (tripartite) systems – Exclusively in Gram negative species (GNB) ♦ A transporter protein ♦ A periplasmic adaptor lipoprotein ♦ A outer membrane channel protein 11
- Page 1 and 2: Role of the Efflux Pumps in Antimic
- Page 3 and 4: Cell wall Bacterial targets for ant
- Page 5 and 6: Drug inactivation Target alteration
- Page 7 and 8: Intracellular accumulation Drug acc
- Page 9: 9 Other bacterial species with know
- Page 13 and 14: PMF secondary transporters Major F
- Page 15 and 16: Efflux-based resistance in Staphylo
- Page 17 and 18: System NorA in S. aureus Antibiotic
- Page 19 and 20: Combination of mechanisms in S. aur
- Page 21 and 22: PmrA-mediated resistance in S. pneu
- Page 23 and 24: Other Gram positives Species System
- Page 25 and 26: 25 Efflux pumps coded by mobile gen
- Page 27 and 28: Efflux pumps of the RND family Bact
- Page 29 and 30: System AcrAB-TolC in E. coli Antibi
- Page 31 and 32: Induction of acrAB-tolC expression
- Page 33 and 34: RND efflux systems in P. aeruginosa
- Page 35 and 36: Acquired resistance in P. aeruginos
- Page 37 and 38: MexXY-mediated adaptive resistance
- Page 39 and 40: Therapeutic implications of efflux
- Page 41: Efflux inhibitors Phenyl-Arginyl ß
Efflux mechanisms: practical implications<br />
Do efflux systems produce clinically relevant levels of resistance ?<br />
Does the expression of drug transporters impair the virulence of<br />
bacterial pathogens ?<br />
What is the prevalence of efflux systems relative to other resistance<br />
mechanisms among the clinical isolates ?<br />
How to recognize efflux mutants in laboratory practice ?<br />
What recommendations can be made to the physician for the<br />
treatment of patients infected with mdr strains ?<br />
10
Change language